Bullish indicating open at $55-$60, IPO prices at $37
Ironwood Pharmaceuticals , Inc. (NASDAQ:IRWD) stock has tumbled to a 52-week low, touching a price level of $1.34 USD. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 4.66 and a market capitalization of $218 million. Analyst price targets range from $3 to $14, suggesting potential upside despite current market conditions. This significant downturn reflects a stark contrast from its performance over the past year, with the company’s shares experiencing a precipitous decline of -84.2%. Investors have been closely monitoring Ironwood as it navigates through a challenging market environment, which has seen the stock struggle to regain its footing. The 52-week low serves as a critical indicator of the current investor sentiment and the hurdles the company faces in the pharmaceutical industry. Despite these challenges, InvestingPro’s analysis indicates an overall "GOOD" financial health score, with 12 additional key insights available for subscribers.
In other recent news, Ironwood Pharmaceuticals reported its fourth-quarter results, revealing adjusted earnings per share of $0.02, which fell short of analyst estimates of $0.06. The company’s revenue for the quarter was $90.55 million, below the expected $92.5 million. Despite the earnings miss, positive developments in Ironwood’s pipeline drug apraglutide for short bowel syndrome captured investors’ attention. The company has started a rolling New Drug Application submission to the FDA, with completion anticipated in the third quarter of 2025. Additionally, data from an open-label extension study showed promising results for patients using apraglutide. Regarding its marketed drug Linzess, Ironwood reported an 11% year-over-year growth in prescription demand for 2024, although U.S. net sales declined by 15% to $916.3 million. Ironwood provided revenue guidance for 2025, projecting $260-290 million, compared to analyst expectations of $287.6 million. The company ended 2024 with $88.6 million in cash and cash equivalents and generated $103.5 million in cash from operations for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.